Sociodemographic differences in utilization and outcomes for temporary cardiovascular mechanical support in the setting of cardiogenic shock - 24/04/21

Riassunto |
Background |
Temporary mechanical circulatory support (MCS) devices are increasingly used in cardiogenic shock, but whether sociodemographic differences by sex, race and/or ethnicity, insurance status, and neighborhood poverty exist in the utilization of these devices is unknown.
Methods |
Retrospective cross-sectional study using the National Inpatient Sample for 2012-2017. Logistic regression models were used to examine predictors of use of temporary MCS devices and for in-hospital mortality, clustering by hospital-year.
Results |
Our study population included 109,327 admissions for cardiogenic shock. Overall, 14.3% of admissions received an intra-aortic balloon pump, 4.2% a percutaneous ventricular assist device, and 1.8% extracorporeal membranous oxygenation (ECMO). After adjusting for age, comorbidities, and hospital characteristics, use of temporary MCS was lower in women compared to men (adjusted odds ratio [aOR] = 0.76, P < .001), Black patients compared to white ones (aOR = 0.73, P < .001), those insured by Medicare (aOR = 0.75, P < .001), Medicaid (aOR = 0.74, P < .001), or uninsured (aOR = 0.90, P = .015) compared to privately insured, and those in the lowest income neighborhoods (aOR = 0.94, P = .003) versus other neighborhoods. Women, admissions covered by Medicare, Medicaid, or uninsured, and those from low-income neighborhoods also had higher mortality rates even after adjustment for MCS implantation.
Conclusions |
There are differences in the use of temporary MCS in the setting of cardiogenic shock among specific populations within the United States. The growing use of MCS for treating cardiogenic shock highlights the need to better understand its impact on outcomes.
Il testo completo di questo articolo è disponibile in PDF.Abbreviations : (a)OR, ECMO, HCUP, IABP, ICD, MCS, NIS, pVAD, RCT
Mappa
| Declarations of interest/disclosures: Dr. Joynt Maddox receives research support from the National Heart, Lung, and Blood Institute (R01HL143421) and National Institute on Aging (R01AG060935), and previously did contract work for the US Department of Health and Human Services. Dr. Amit P. Amin has received funding from the National Center for Advancing Translational Sciences of the National Institutes of Health (UL1TR000448, KL2TR000450, TL1TR000449), National Cancer Institute of the National Institutes of Health (1KM1CA156708-01), and an AHRQ R18 grant award (R18HS0224181-01A1). He also has unrestricted grants from Volcano corporation and MedAxiom Synergistic Healthcare Solutions Austin, TX, and is a consultant to Terumo, GE Healthcare and AstraZeneca. Dr. Lasala is a consultant for Abiomed, Abbott, Boston Scientific, Chiesi, and Gore. All other authors report no financial conflicts or relationships. |
Vol 236
P. 87-96 - giugno 2021 Ritorno al numeroBenvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?
